At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 39 enrolled
Drug / intervention
BI 703621 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 706321 in Healthy Male and Female Subjects (Doubleblind, Randomised, Placebo-controlled, Parallel Group Design)
In Brief
A Phase 1 clinical trial evaluating BI 703621, Placebo, and 1 other intervention for Healthy. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJan 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedJan 27, 2020
Enrollment StartJan 30, 2020
Primary CompletionNov 24, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.4 years ago
Interventions
BI 703621drug
BI 703621
Placebodrug
Placebo
Midazolamdrug
Midazolam